195 related articles for article (PubMed ID: 21209794)
1. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.
Walensky RP; Wood R; Ciaranello AL; Paltiel AD; Lorenzana SB; Anglaret X; Stoler AW; Freedberg KA;
PLoS Med; 2010 Dec; 7(12):e1000382. PubMed ID: 21209794
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
Bender MA; Kumarasamy N; Mayer KH; Wang B; Walensky RP; Flanigan T; Schackman BR; Scott CA; Lu Z; Freedberg KA
Clin Infect Dis; 2010 Feb; 50(3):416-25. PubMed ID: 20043752
[TBL] [Abstract][Full Text] [Related]
4. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of ART in resource-limited countries.
Loubiere S; Meiners C; Sloan C; Freedberg KA; Yazdanpanah Y
Curr Opin HIV AIDS; 2010 May; 5(3):225-31. PubMed ID: 20539078
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
8. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
9. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
[TBL] [Abstract][Full Text] [Related]
10. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
Brooks K; Diero L; DeLong A; Balamane M; Reitsma M; Kemboi E; Orido M; Emonyi W; Coetzer M; Hogan J; Kantor R
J Int AIDS Soc; 2016; 19(1):20798. PubMed ID: 27231099
[TBL] [Abstract][Full Text] [Related]
11. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
[TBL] [Abstract][Full Text] [Related]
12. Reasons for first line ART modification over the years during the ART scale up in Uganda.
Castelnuovo B; Mubiru F; Kalule I; Kiragga A
AIDS Res Ther; 2019 Oct; 16(1):31. PubMed ID: 31597561
[TBL] [Abstract][Full Text] [Related]
13. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.
Hontelez JA; de Vlas SJ; Tanser F; Bakker R; Bärnighausen T; Newell ML; Baltussen R; Lurie MN
PLoS One; 2011; 6(7):e21919. PubMed ID: 21799755
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.
Yazdanpanah Y; Wolf LL; Anglaret X; Gabillard D; Walensky RP; Moh R; Danel C; Sloan CE; Losina E; Freedberg KA;
Antivir Ther; 2010; 15(3):351-61. PubMed ID: 20516555
[TBL] [Abstract][Full Text] [Related]
16. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
Kimmel AD; Weinstein MC; Anglaret X; Goldie SJ; Losina E; Yazdanpanah Y; Messou E; Cotich KL; Walensky RP; Freedberg KA;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):258-68. PubMed ID: 20404739
[TBL] [Abstract][Full Text] [Related]
17. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
18. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
[TBL] [Abstract][Full Text] [Related]
19. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
20. Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings.
Leisegang R; Maartens G; Hislop M; Regensberg L; Cleary S
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S3. PubMed ID: 20594369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
